Drugs / GSK A/turkey H5N1 Influenza vaccine
GSK A/turkey H5N1 Influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00771615 | Oct 2008 → May 2009 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK A/turkey H5N1 Influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00771615 ↗ |
| Known as | A/turkey/Turkey/1/2005 (H5N1) vaccine | “adults (n=469) randomised 15 months previously to receive an A/Indonesia/5/2005 (H5N1) influenza vaccine (3.75 μg haemagglutinin antigen [HA]) administered alone or in...” PMID 21554915 ↗ May 2011 |
| Known as | GSK 1557484A | “The purpose of this observer-blind study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic when given to adults aged 18-64 years.” NCT00771615 ↗ |
| Modality | Vaccine | “The purpose of this observer-blind study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic when given to adults aged 18-64 years.” NCT00771615 ↗ |
| Route | Intramuscular | “The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.” NCT00771615 ↗ |